

in this issue	1151	Effectiveness of organised versus opportunistic mammography screening <i>J.-L. Bulliard, C. Ducros, C. Jemelin, B. Arzel, G. Fioretta & F. Levi</i>	1199
editorial		Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy <i>P. Hadji, M. Ziller, D. G. Kieback, W. Dornoff, H. W. Tessen, T. Menschik, J. Kuck, F. Melchert & A. Hasenburg</i>	1203
The use of sedation to relieve cancer patients' suffering at the end of life: addressing critical issues <i>N. Cherny</i>	1153	Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802) <i>N. Katsumata, T. Watanabe, H. Minami, K. Aogi, T. Tabei, M. Sano, N. Masuda, J. Andoh, T. Ikeda, T. Shibata & S. Takashima</i>	1210
review		gastrointestinal tumors MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events <i>S. de Vogel, M. P. Weijnenberg, J. G. Herman, K. A. D. Wouters, A. F. P. M. de Goeij, P. A. van den Brandt, A. P. de Bruïne & M. van Engeland</i>	1216
What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? <i>C. H. Barrios, C. Sampaio, J. Vinholes & R. Caponero</i>	1157	Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer <i>S. J. Cohen, C. J. A. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath, N. Y. Gabrail, J. Picus, M. A. Morse, E. Mitchell, M. C. Miller, G. V. Doyle, H. Tissing, L. W. M. M. Terstappen & N. J. Meropol</i>	1223
original articles		PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma <i>A. Buhmeida, R. Bendardaf, M. Hilska, J. Laine, Y. Collan, M. Laato, K. Syrjänen & S. Pyrhönen</i>	1230
quality of life / supportive care / palliative care		Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer <i>N. Kemeny, M. Capanu, M. D'Angelica, W. Jarnagin, D. Haviland, R. Dematteo & Y. Fong</i>	1236
Palliative sedation therapy does not hasten death: results from a prospective multicenter study <i>M. Maltoni, C. Pittureri, E. Scarpi, L. Piccinini, F. Martini, P. Turci, L. Montanari, O. Nanni & D. Amadori</i>	1163	Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer <i>B. Burtness, M. Gibson, B. Egleston, R. Mehra, L. Thomas, R. Sipples, M. Quintanilla, J. Lacy, S. Watkins, J. R. Murren & A. A. Forastiere</i>	1242
Comprehensive clinical follow-up of late effects in childhood cancer survivors shows the need for early and well-timed intervention <i>J. W. Han, S. Y. Kwon, S. C. Won, Y. J. Shin, J. H. Ko & C. J. Lyu</i>	1170		
breast cancer			
A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer <i>M. Colleoni, V. Bagnardi, N. Rotmensz, S. Dellapasqua, G. Viale, G. Pruneri, P. Veronesi, R. Torrisi, A. Luini, M. Intra, V. Galimberti, E. Montagna & A. Goldhirsch</i>	1178		
Preoperative weekly cisplatin–epirubicin–paclitaxel with G-CSF support in triple-negative large operable breast cancer <i>G. Frasci, P. Comella, M. Rinaldo, G. Iodice, M. Di Bonito, M. D'Aiuto, A. Petrillo, S. Lastoria, C. Siani, G. Comella & G. D'Aiuto</i>	1185		
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy <i>V. Guarneri, F. Piacentini, G. Ficarra, A. Frassoldati, R. D'Amico, S. Giovannelli, A. Maiorana, G. Jovic & P. Conte</i>	1193		

Continued overleaf

lung cancer

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer
E. H. Tan, J. Rolski, T. Grodzki, C. P. Schneider, U. Gatzemeier, P. Zatloukal, E. Aitini, G. Carteni, H. Riska, Y. H. Tsai & R. Abratt 1249

The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma
D. Planchard, J. Domont, E. Taranchon, I. Monnet, J. Tredaniel, R. Caliandro, P. Validire, B. Besse, J.-C. Soria & P. Fourret 1257

urogenital tumors

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
C. N. Sternberg, H. Dumez, H. Van Poppel, I. Skoneczna, A. Sella, G. Daugaard, T. Gil, J. Graham, P. Carpentier, F. Calabro, L. Collette & D. Lacombe for the EORTC Genitourinary Tract Cancer Group 1264

hematologic malignancies

FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value
J. Markova, C. Kobe, M. Skopalova, K. Klaskova, K. Dedekova, A. Plütschow, H. T. Eich, M. Dietlein, A. Engert & T. Kozak 1270

head and neck cancer

Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma
C. M. Nutting, C. M. L. van Herpen, A. B. Miah, S. A. Bhide, J.-P. Machiels, J. Buter, C. Kelly, D. de Raucourt & K. J. Harrington 1275

letters to the editor

Travel warning with capecitabine
M. Wong, S.-P. Choo & E.-H. Tan 1281

Tamoxifen contraindicated in women with hereditary angioedema?
C. Rousset-Jablonski, J.-C. Thalabard & A. Gompel 1281

Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP?
M. Khasraw & S. Baron-Hay 1282

Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis
I. G. Glezerman 1283

BRCA2 splice site mutations in an Italian breast/ovarian cancer family
O. Díez & S. Gutiérrez-Enríquez 1285

Reply to BRCA2 splice site mutations in an Italian breast/ovarian cancer family
M. Pensabene, I. Spagnoletti, I. Capuano, C. Condello, S. Pepe, A. Contegiacomo, G. Lombardi, G. Bevilacqua & M.A. Caligo 1285